Trial Profile
Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary) ; Tamsulosin (Primary)
- Indications Lower urinary tract symptoms
- Focus Biomarker; Therapeutic Use
- 16 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Oct 2011 New trial record